Stride Post Latest News
Related Articles
According to the latest report by IMARC Group, titled “India Generic Injectables Market: Industry Trends, Share, Size, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the india generic injectables market growth. The India generic injectables market reached a value of US$ 2.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2027, exhibiting a CAGR of 12.8% during 2022-2027.
Generic injectables are pharmaceutical drugs with the similar active ingredients, strength, dosage, and administration route as that of their branded injectables. Some of common product variants, include Prevnar 13, Eliquis, Ibrance, Lyrica, Xeljanz, etc. Generic injectables facilitate the quick onset of action, precise and adjustable dosing, and predictable bioavailability. Moreover, these injectables cost lesser than their branded counterparts, which helps in managing overhead costs related to pharma products.
Request Free Sample Report: https://www.imarcgroup.com/india-generic-injectables-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Market Trends:
The growing prevalence of chronic diseases in India, due to unhealthy dietary habits and sedentary lifestyles of the consumers, is primarily catalyzing the market for generic injectables market. Furthermore, the increasing investments by the Indian government to introduce innovative generic injectables for providing effective drug administration and enabling faster recovery of patients are also providing a thrust to the market. Additionally, several technological advancements in the drug delivery systems, such as the introduction of self-injection devices, are propelling the market growth. Various other factors, including increasing penetration of health insurance companies and the upcoming patent expiry of several blockbuster medicines, are expected to further drive the market growth over the forecasted period.
Breakup by Therapeutic Area:
- Oncology
- Anaesthesia
- Anti-infectives
- Parenteral Nutrition
- Cardiovascular
Breakup by Container:
- Vials
- Ampoules
- Premix
- Prefilled Syringes
Breakup by Distribution Channel:
- Hospitals
- Retail Pharmacy
Breakup by Region:
- North India
- West and Central India
- South India
- East India
Competitive Landscape:
The report has also analysed the competitive landscape of the market along with the profiles of the key players.
Ask Analyst for Customization and Explore Full Report with TOC List of Figure: https://www.imarcgroup.com/india-generic-injectables-market
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
